Cargando…

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma is one of the most lethal cancers worldwide. Novel prognostic and/or predictive biomarkers are urgently needed to improve patient management. Alpha‐fetoprotein (AFP) is a well‐established and widely used biomarker for hepatocellular carcinoma. However, diagnostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czauderna, Carolin, Schmidtmann, Irene, Koch, Sandra, Pilz, Lukas, Heinrich, Sophia, Otto, Gerd, Mittler, Jens, Lang, Hauke, Kloeckner, Roman, Düber, Christoph, Sprinzl, Martin F., Worns, Marcus A., Galle, Peter R., Marquardt, Jens U., Weinmann, Arndt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Hepatobiliary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259127/ http://dx.doi.org/10.1177/2050640620972611

Ejemplares similares

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome
por: Heinrich, Sophia, et al.
Publicado: (2022)

Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week
por: Pitton, Michael Bernhard, et al.
Publicado: (2021)

Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
por: Weinmann, Arndt, et al.
Publicado: (2015)

Quantitative assessment of washout in hepatocellular carcinoma using MRI
por: Kloeckner, Roman, et al.
Publicado: (2016)

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question
por: Pitton, Michael B., et al.
Publicado: (2020)

Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features
por: Liu, Jun, et al.
Publicado: (2021)

Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany
por: Labenz, Christian, et al.
Publicado: (2021)

Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas
por: Castven, Darko, et al.
Publicado: (2017)

Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score
por: Müller, Lukas, et al.
Publicado: (2020)

Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones
por: Mittler, Jens, et al.
Publicado: (2022)

Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy
por: Müller, Lukas, et al.
Publicado: (2022)

Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
por: Müller, Lukas, et al.
Publicado: (2023)

The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study
por: Mähringer-Kunz, Aline, et al.
Publicado: (2021)

Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?
por: Heinrich, Stefan, et al.
Publicado: (2022)

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
por: Thol, Felix, et al.
Publicado: (2021)

The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy
por: Müller, Lukas, et al.
Publicado: (2022)

Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

(13)C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Gairing, Simon Johannes, et al.
Publicado: (2022)

COVID‐19 mortality in cirrhosis is determined by cirrhosis‐associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry
por: Brozat, Jonathan F., et al.
Publicado: (2022)

Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study
por: Stoehr, Fabian, et al.
Publicado: (2022)

Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial
por: Kloeckner, Roman, et al.
Publicado: (2014)

Development and validation of a prognostic score for long‐term transplant‐free survival in autoimmune hepatitis type 1
por: Biewenga, Maaike, et al.
Publicado: (2021)

Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
por: Müller, Lukas, et al.
Publicado: (2022)

Suppressed serological vitamin A in patients with liver cirrhosis is associated with impaired liver function and clinical detoriation
por: Nagel, Michael, et al.
Publicado: (2022)

Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function
por: Müller, Lukas, et al.
Publicado: (2021)

Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?
por: Müller, Lukas, et al.
Publicado: (2021)

Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases
por: Cheung, Helen M. C., et al.
Publicado: (2018)

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells
por: Castven, Darko, et al.
Publicado: (2021)

Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomy
por: Cheung, Helen M. C., et al.
Publicado: (2018)

Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study
por: Wei, Hong, et al.
Publicado: (2023)

CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
por: Colagrande, S., et al.
Publicado: (2020)

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
por: Saha, Supriya K., et al.
Publicado: (2016)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans
por: Guler, Ezgi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pggr7lpc3cqoffh77hv5so7t9t